Sanofi · 3 hours ago
Strategic Account Manager, Columbus
Sanofi is an R&D-driven, AI-powered biopharma company committed to improving people’s lives. The Strategic Account Manager will support Sanofi's largest customers by educating stakeholders on the operational aspects of Tzield administration and collaborating with internal teams to ensure effective account management and support.
Health CareLife SciencePharmaceuticalTherapeutics
Responsibilities
Educate stakeholders on operational aspects of Tzield administration and integration (sharing best practices as necessary) to align on needed resources and share best practices regarding internal pathways/processes most appropriate for Tzield utilization, and internal pathways/processes
Share insights and best practices from publicly available resources to support infrastructure planning for Tzield
Develop a deep understanding of each account’s T1D care landscape, including screening, evaluation, and treatment logistics
Collaborate with Sanofi teams to create and execute strategic account plans to ensure comprehensive account support and help establish the account as an effective site of care
Qualification
Required
Bachelor's degree required
Broad understanding of healthcare business, with proven track record of C- and D-suite engagement
5+ years of field sales or account management experience
Strong leadership, project management, and communication skills
Robust business acumen and ability to develop and execute strategic plans
Have a valid driver's license
Ability to travel up to 80% of the time to customers, conventions, training, and other internal meetings
Preferred
MBA or other advanced degree preferred
Benefits
High-quality healthcare
Prevention and wellness programs
At least 14 weeks’ gender-neutral parental leave
Company car through the Company’s FLEET program
Company
Sanofi
Sanofi is a global biopharma company focused on prescription drugs, vaccines, and treatments for chronic, rare, and infectious diseases.
Funding
Current Stage
Public CompanyTotal Funding
$6.97BKey Investors
Blackstone Life SciencesEvotec
2025-10-28Post Ipo Debt· $3B
2025-06-17Post Ipo Debt· $1.74B
2025-03-05Post Ipo Debt· $1.59B
Recent News
2026-01-25
BioWorld Financial Watch
2026-01-25
2026-01-24
Company data provided by crunchbase